, levels of which are elevated in ESRD (5). Lp(a) is composed of an LDL particle covalently bonded to apolipoprotein(a) [apo(a)], a glycoprotein with a highly variable number of Kringle-IV (K-IV) units related to a polymorphism encoded in the apo(a) gene. Lp(a) levels are inversely related to apo(a) isoform size (6).Many previous studies in the general population have found that high Lp(a) levels (7) and small apo(a) size (8 -12) are associated with ASCVD. The few studies of Lp(a) in ESRD have provided conflicting results (13-15), with the only prospective study to evaluate both Lp(a) and apo(a) size reporting that small apo(a) size but not Lp(a) level is associated with increased ASCVD (13).The Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study, a prospective study of outcomes among black and white incident dialysis patients, previously found that small apo(a) size but not Lp(a) level was associated with total mortality (16). The current study, based on the CHOICE cohort, tested the a priori hypothesis that small apo(a) size but not high Lp(a) level is associated with prospectively ascertained ASCVD in a national, biracial cohort of patients who begin dialysis.
Materials and Methods
Study Design and PopulationThe CHOICE Study enrolled 1041 participants in 19 states from 81 dialysis clinics associated with Dialysis Clinic, Incorporated (DCI; Nashville, TN; n ϭ 923 from 79 clinics), New Haven CAPD (New Haven, CT; n ϭ 86 from one clinic), or Saint Raphael's Hospital (New Haven, CT; n ϭ 32 from one clinic) from October 1995 to June 1998. Enrollment occurred a median of 1.6 mo after first dialysis (98% within 4 mo). Blood was obtained only at the DCI clinics, and samples were available for determination of Lp(a) level and apo(a) size for 872 (93.6%) of the 923 DCI participants; 833 (90.2%) were eligible for Lp(a)-related analysis. Enrollment criteria included initiation of dialysis in the preceding 3 mo, ability to give written informed consent, age over 17 yr, and ability to speak English or Spanish. The Johns Hopkins University School of Medicine Institutional Review Board approved the protocol.